359 related articles for article (PubMed ID: 32359337)
1. Is It the Twilight of BACE1 Inhibitors?
Hrabinova M; Pejchal J; Kucera T; Jun D; Schmidt M; Soukup O
Curr Neuropharmacol; 2021; 19(1):61-77. PubMed ID: 32359337
[TBL] [Abstract][Full Text] [Related]
2. Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Moussa CE
Expert Opin Investig Drugs; 2017 Oct; 26(10):1131-1136. PubMed ID: 28817311
[TBL] [Abstract][Full Text] [Related]
3. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
4. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
[TBL] [Abstract][Full Text] [Related]
5. Targeting the β secretase BACE1 for Alzheimer's disease therapy.
Yan R; Vassar R
Lancet Neurol; 2014 Mar; 13(3):319-29. PubMed ID: 24556009
[TBL] [Abstract][Full Text] [Related]
6. Investigational BACE inhibitors for the treatment of Alzheimer's disease.
Imbimbo BP; Watling M
Expert Opin Investig Drugs; 2019 Nov; 28(11):967-975. PubMed ID: 31661331
[No Abstract] [Full Text] [Related]
7. [BACE1 inhibitors for the treatment of Alzheimer disease].
Tomita T
Nihon Rinsho; 2016 Mar; 74(3):427-31. PubMed ID: 27025081
[TBL] [Abstract][Full Text] [Related]
8. A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.
Das B; Yan R
CNS Drugs; 2019 Mar; 33(3):251-263. PubMed ID: 30830576
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
Luo X; Yan R
Int J Clin Exp Pathol; 2010 Jul; 3(6):618-28. PubMed ID: 20661410
[TBL] [Abstract][Full Text] [Related]
10. New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer's Disease Models.
Resende R; Ferreira-Marques M; Moreira P; Coimbra JRM; Baptista SJ; Isidoro C; Salvador JAR; Dinis TCP; Pereira CF; Santos AE
J Alzheimers Dis; 2020; 76(4):1317-1337. PubMed ID: 32597812
[TBL] [Abstract][Full Text] [Related]
11. BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology.
Koelsch G
Molecules; 2017 Oct; 22(10):. PubMed ID: 29027981
[TBL] [Abstract][Full Text] [Related]
12. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
13. BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status.
Evin G; Hince C
Drugs Aging; 2013 Oct; 30(10):755-64. PubMed ID: 23842796
[TBL] [Abstract][Full Text] [Related]
14. The β-Secretase BACE1 in Alzheimer's Disease.
Hampel H; Vassar R; De Strooper B; Hardy J; Willem M; Singh N; Zhou J; Yan R; Vanmechelen E; De Vos A; Nisticò R; Corbo M; Imbimbo BP; Streffer J; Voytyuk I; Timmers M; Tahami Monfared AA; Irizarry M; Albala B; Koyama A; Watanabe N; Kimura T; Yarenis L; Lista S; Kramer L; Vergallo A
Biol Psychiatry; 2021 Apr; 89(8):745-756. PubMed ID: 32223911
[TBL] [Abstract][Full Text] [Related]
15. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
Vassar R
Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
[TBL] [Abstract][Full Text] [Related]
16. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
17. Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease.
Zhang C
Discov Med; 2012 Sep; 14(76):189-97. PubMed ID: 23021373
[TBL] [Abstract][Full Text] [Related]
18. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
Read J; Suphioglu C
Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
[TBL] [Abstract][Full Text] [Related]
20. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
Hook G; Hook V; Kindy M
J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
